FDA gives pri­or­i­ty re­view to new Keytru­da sBLA; As­traZeneca's Pearl signs asth­ma de­vel­op­ment pact with Avil­lion

→ The FDA is giv­ing pri­or­i­ty re­view to Mer­ck’s $MRK an­ti-PD-1 ther­a­py, Keytru­da, for a new sup­ple­men­tal bi­o­log­ics li­cense ap­pli­ca­tion (sBLA). The ap­pli­ca­tion is ask­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER